IRF4 and Miyoshi myopathy: BRD inhibitors re-sensitize several IMiD-resistant human MM cell lines to lenalidomide by targeting the IRF4/MYC axis and also increase the sensitivity of IMiD-sensitive cell lines to lenalidomide.